Trastuzumab Deruxtecan Is Active in HER2 Low-Expressing Breast Cancer
Pharma & biotech2020-06-10
80 Views
The novel HER2-directed antibody-drug conjugate trastuzumab deruxtecan-nxki demonstrated promising antitumor activity in patients with heavily pretreated, HER2 low-expressing advanced or metastatic breast cancer.
Source: OncLive
The news, reports, views and opinions of authors (or source) expressed are their own and do not necessarily represent the views of CRWE World.
Berkshire Hathaway Inc. (NYSE: BRK.A) (NYSE: BRK.B) Reports Fourth Quarter and Full Year 2020
